About SporeGen
SporeGen is a company based in Egham (United Kingdom) founded in 2011.. SporeGen offers products and services including SporeVax, Bacillus Probiotics, Drug Delivery System, and Contract Research. SporeGen operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Egham, United Kingdom
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sporegen Limited
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$270.08 K (USD), Grant
Mar 01, 2015
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SporeGen
SporeGen offers a comprehensive portfolio of products and services, including SporeVax, Bacillus Probiotics, Drug Delivery System, and Contract Research. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Heat-stable mucosal vaccines using bacterial spores for oral delivery.
Development of carotenoid-rich strains for novel food applications.
Bacillus spores for directing anti-tumor drugs to cancerous cells.
Genetic engineering and safety assessments for Bacillus applications.
Unlock access to complete
Unlock access to complete
Funding Insights of SporeGen
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $270,081
-
First Round
First Round
(02 Jan 2014)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2015 | Amount | Grant - SporeGen | Valuation |
investors |
|
| Jan, 2015 | Amount | Grant - SporeGen | Valuation |
investors |
|
| Jan, 2015 | Amount | Grant - SporeGen | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SporeGen
SporeGen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SporeGen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SporeGen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sporegen Comparisons
Competitors of SporeGen
SporeGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sporegen
Frequently Asked Questions about SporeGen
When was SporeGen founded?
SporeGen was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Where is SporeGen located?
SporeGen is headquartered in Egham, United Kingdom. It is registered at Egham, Surrey, United Kingdom.
Who is the current CEO of SporeGen?
Phan Chien Thang is the current CEO of SporeGen.
What does SporeGen do?
SporeGen was founded in 2011 in Egham, United Kingdom, focusing on Bacillus species applications in biotechnology. Vaccine delivery platforms using bacterial spores for antigen adsorption are developed, alongside carotenoid-rich strains and reagents for Bacillus subtilis and Clostridium difficile. Probiotic foods, contract research services, and in vivo studies for Clostridium difficile are offered, with a drug delivery system for antitumor compounds under exploration.
Who are the top competitors of SporeGen?
SporeGen's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does SporeGen offer?
SporeGen offers SporeVax, Bacillus Probiotics, Drug Delivery System, and Contract Research.
Who are SporeGen's investors?
SporeGen has 1 investor. Key investors include European Union.